674 related articles for article (PubMed ID: 16618572)
1. Intensity-modulated radiation therapy, protons, and the risk of second cancers.
Hall EJ
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):1-7. PubMed ID: 16618572
[TBL] [Abstract][Full Text] [Related]
2. The inaugural Frank Ellis Lecture--latrogenic cancer: the impact of intensity-modulated radiotherapy.
Hall EJ
Clin Oncol (R Coll Radiol); 2006 May; 18(4):277-82. PubMed ID: 16703744
[TBL] [Abstract][Full Text] [Related]
3. [IMRT combined to IGRT: increase of the irradiated volume. Consequences?].
Lisbona A; Averbeck D; Supiot S; Delpon G; Ali D; Vinas F; Diana C; Murariu C; Lagrange JL
Cancer Radiother; 2010 Oct; 14(6-7):563-70. PubMed ID: 20729117
[TBL] [Abstract][Full Text] [Related]
4. Modelling carcinogenesis after radiotherapy using Poisson statistics: implications for IMRT, protons and ions.
Jones B
J Radiol Prot; 2009 Jun; 29(2A):A143-57. PubMed ID: 19454805
[TBL] [Abstract][Full Text] [Related]
5. Radiation-induced cancers from modern radiotherapy techniques: intensity-modulated radiotherapy versus proton therapy.
Yoon M; Ahn SH; Kim J; Shin DH; Park SY; Lee SB; Shin KH; Cho KH
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1477-85. PubMed ID: 19879701
[TBL] [Abstract][Full Text] [Related]
6. A review of the impact of photon and proton external beam radiotherapy treatment modalities on the dose distribution in field and out-of-field; implications for the long-term morbidity of cancer survivors.
Palm A; Johansson KA
Acta Oncol; 2007; 46(4):462-73. PubMed ID: 17497313
[TBL] [Abstract][Full Text] [Related]
7. Effect of intensity-modulated pelvic radiotherapy on second cancer risk in the postoperative treatment of endometrial and cervical cancer.
Zwahlen DR; Ruben JD; Jones P; Gagliardi F; Millar JL; Schneider U
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):539-45. PubMed ID: 19427555
[TBL] [Abstract][Full Text] [Related]
8. Estimation of risk of radiation-induced carcinogenesis in adolescents with nasopharyngeal cancer treated using sliding window IMRT.
Sharma SD; Upreti RR; Laskar S; Tambe CM; Deshpande DD; Shrivastava SK; Dinshaw KA
Radiother Oncol; 2008 Feb; 86(2):177-81. PubMed ID: 18082906
[TBL] [Abstract][Full Text] [Related]
9. A dosimetric comparison of proton and intensity-modulated photon radiotherapy for pediatric parameningeal rhabdomyosarcomas.
Kozak KR; Adams J; Krejcarek SJ; Tarbell NJ; Yock TI
Int J Radiat Oncol Biol Phys; 2009 May; 74(1):179-86. PubMed ID: 19019562
[TBL] [Abstract][Full Text] [Related]
10. The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy.
Kry SF; Salehpour M; Followill DS; Stovall M; Kuban DA; White RA; Rosen II
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1195-203. PubMed ID: 15990025
[TBL] [Abstract][Full Text] [Related]
11. Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer.
Vargas C; Fryer A; Mahajan C; Indelicato D; Horne D; Chellini A; McKenzie C; Lawlor P; Henderson R; Li Z; Lin L; Olivier K; Keole S
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):744-51. PubMed ID: 17904306
[TBL] [Abstract][Full Text] [Related]
12. Dosimetric advantages of IMPT over IMRT for laser-accelerated proton beams.
Luo W; Li J; Fourkal E; Fan J; Xu X; Chen Z; Jin L; Price R; Ma CM
Phys Med Biol; 2008 Dec; 53(24):7151-66. PubMed ID: 19033641
[TBL] [Abstract][Full Text] [Related]
13. A comparison of out-of-field dose and its constituent components for intensity-modulated radiation therapy versus conformal radiation therapy: implications for carcinogenesis.
Ruben JD; Lancaster CM; Jones P; Smith RL
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1458-64. PubMed ID: 20950947
[TBL] [Abstract][Full Text] [Related]
14. Should positive phase III clinical trial data be required before proton beam therapy is more widely adopted? No.
Suit H; Kooy H; Trofimov A; Farr J; Munzenrider J; DeLaney T; Loeffler J; Clasie B; Safai S; Paganetti H
Radiother Oncol; 2008 Feb; 86(2):148-53. PubMed ID: 18237800
[TBL] [Abstract][Full Text] [Related]
15. Proton radiotherapy for childhood ependymoma: initial clinical outcomes and dose comparisons.
MacDonald SM; Safai S; Trofimov A; Wolfgang J; Fullerton B; Yeap BY; Bortfeld T; Tarbell NJ; Yock T
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):979-86. PubMed ID: 18325681
[TBL] [Abstract][Full Text] [Related]
16. The risk of radiation-induced second cancers in the high to medium dose region: a comparison between passive and scanned proton therapy, IMRT and VMAT for pediatric patients with brain tumors.
Moteabbed M; Yock TI; Paganetti H
Phys Med Biol; 2014 Jun; 59(12):2883-99. PubMed ID: 24828559
[TBL] [Abstract][Full Text] [Related]
17. The effect of intensity-modulated radiotherapy on radiation-induced second malignancies.
Ruben JD; Davis S; Evans C; Jones P; Gagliardi F; Haynes M; Hunter A
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1530-6. PubMed ID: 18207670
[TBL] [Abstract][Full Text] [Related]
18. Risk of developing second cancer from neutron dose in proton therapy as function of field characteristics, organ, and patient age.
Zacharatou Jarlskog C; Paganetti H
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):228-35. PubMed ID: 18571337
[TBL] [Abstract][Full Text] [Related]
19. The normal tissue sparing obtained with simultaneous treatment of pelvic lymph nodes and bladder using intensity-modulated radiotherapy.
Søndergaard J; Høyer M; Petersen JB; Wright P; Grau C; Muren LP
Acta Oncol; 2009; 48(2):238-44. PubMed ID: 18759144
[TBL] [Abstract][Full Text] [Related]
20. Major reduction of monitor units with the avoidance of leaf-sequencing step by direct aperture based IMRT optimisation.
Seppälä J; Lahtinen T; Kolmonen P
Acta Oncol; 2009; 48(3):426-30. PubMed ID: 18766997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
